Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer.
Van Nostrand
D
D
Division of Nuclear Medicine, Department of Medicine, Washington Hospital Center and Professor of Medicine, Georgetown University School of Medicine, Washington, DC 20010, USA. douglas.van.nostrand@medstar.net
D018678:Cholinergic Agents / Q000627:therapeutic use; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000209:etiology* / Q000517:prevention & control; D018987:Salivary Ducts / Q000528:radiation effects; D012472:Salivation / Q000528:radiation effects; D012793:Sialadenitis / Q000209:etiology* / Q000517:prevention & control; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D014987:Xerostomia / Q000209:etiology / Q000517:prevention & control
D018678:Cholinergic Agents; D007457:Iodine Radioisotopes